Madrigal Pharmaceuticals, Inc.
MDGL
Rankning i aktier
#1943
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical... Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Aktiekurs
$469.52
Marknadsvärde
$10.85B
Förändring (1 dag)
5.02%
Förändring (1 år)
6.72%
Land
US
Handel Madrigal Pharmaceuticals, Inc. (MDGL)
Kategori
Healthcare
Antal utestående aktier för Madrigal Pharmaceuticals, Inc. (MDGL)
Antal utestående aktier per June 2026: 29.15M
Enligt de senaste finansiella rapporterna och aktiekursen för Madrigal Pharmaceuticals, Inc. är det aktuella antalet utestående aktier 29.15M. I slutet av December 2023 hade företaget 18.69M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Madrigal Pharmaceuticals, Inc. (MDGL) från 2001 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 29.15M | 37.01% |
| 2024 | 21.27M | 13.83% |
| 2023 | 18.69M | 9.05% |
| 2022 | 17.14M | 3.64% |
| 2021 | 16.54M | 7.04% |
| 2020 | 15.45M | 0.34% |
| 2019 | 15.40M | 4.04% |
| 2018 | 14.80M | 20.84% |
| 2017 | 12.25M | 135.25% |
| 2016 | 5.21M | 2,943.65% |
| 2015 | 171.01K | -93.92% |
| 2014 | 2.81M | 38.76% |
| 2013 | 2.03M | 19.51% |
| 2012 | 1.70M | 25.89% |
| 2011 | 1.35M | 16.91% |
| 2010 | 1.15M | 19.09% |
| 2009 | 968.21K | 0.45% |
| 2008 | 963.86K | 3.91% |
| 2007 | 927.59K | 45.81% |
| 2006 | 636.14K | 0.05% |
| 2005 | 635.80K | 18.98% |
| 2004 | 534.39K | -14.41% |
| 2003 | 624.37K | 81.48% |
| 2002 | 344.04K | 310.87% |
| 2001 | 83.74K | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 771.15% |
US
|
|
| 396.00M | 1,258.71% |
US
|
|
| 478.91M | 1,543.19% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 113.36% |
NL
|
